Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors (2021)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.1016/j.annonc.2021.08.1377
- Subjects: IMUNOLOGIA; METABOLISMO; GLICOSE
- Language: Inglês
- Imprenta:
- Source:
- Título: Annals of Oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 32, supl. S5, p. S846-S847, res. 993P, 2021
- Conference titles: European Society for Medical Oncology Congress - ESMO
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
- Licença: publisher-specific-oa
-
ABNT
SILVA, S. B et al. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.annonc.2021.08.1377. Acesso em: 28 dez. 2025. , 2021 -
APA
Silva, S. B., Wanderley, C. W. de S., Marin, J. F. G., Macedo, M. P. de, Nascimento, E. .C. T. do, Antonacio, F. F., et al. (2021). Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors. Annals of Oncology. Amterdam: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.annonc.2021.08.1377 -
NLM
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377 -
Vancouver
Silva SB, Wanderley CW de S, Marin JFG, Macedo MP de, Nascimento E .CT do, Antonacio FF, Cunha F de Q, Castro Jr. G de. Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors [Internet]. Annals of Oncology. 2021 ; 32 S846-S847.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1016/j.annonc.2021.08.1377 - Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Platelets fuel the inflammasome activation of innate immune cells
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Controle da migracao de neutrofilos por fatores liberados de macrofagos estimulados com endotoxina de escherichia coli
- Edema de pata em cobaias: modelo para estudos da reacao inflamatoria de origem imunologica
- Comparison of five methods for the determination of lethal dose in acute toxicity studies
Informações sobre o DOI: 10.1016/j.annonc.2021.08.1377 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003232368.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
